MedTrace Logo

A Study on the Use of Canakinumab Among Familial Mediterranean Fever and Still's Disease Patients

NCT07517250 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 160

Last updated 2026-05-22

No results posted yet for this study

Summary

This study aims to assess and characterize the treatment patterns, and long-term clinical outcomes and demographic characteristics of patients diagnosed with Familial Mediterranean fever (FMF) and Still's disease (including systemic juvenile idiopathic arthritis \[SJIA\] and adult-onset Still's disease \[AOSD\]) that received canakinumab for at least 6 months.

Conditions

  • Familial Mediterranean Fever
  • Still Disease
  • Systemic Juvenile Idiopathic Arthritis
  • Adult-Onset Still Disease

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Eligibility

Min Age
1 Year
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-03-15
Primary Completion
2027-03-03
Completion
2027-03-03

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07517250 on ClinicalTrials.gov